Dec 11 (Reuters) - Correvio Pharma Corp CORV.TO :
* CORREVIO ANNOUNCES INTENTION TO EXPLORE STRATEGIC ALTERNATIVES TO MAXIMIZE STAKEHOLDER VALUE
* CORREVIO PHARMA CORP - POTENTIAL STRATEGIC ALTERNATIVES THAT MAY BE EVALUATED INCLUDE, BUT ARE NOT LIMITED TO, AN ACQUISITION, MERGER
* CORREVIO PHARMA - TAKING STEPS TO REDUCE OPERATING COSTS OUTSIDE CORE EUROPEAN COMMERCIAL BUSINESS & TRANSACTION COMMITTEE FORMED WITHIN BOARD
* CORREVIO PHARMA CORP - CORREVIO'S EX-U.S. COMMERCIAL PORTFOLIO IS ON TRACK TO DELIVER GREATER THAN $30 MILLION IN REVENUE IN 2019
* CORREVIO PHARMA - WILL IMMEDIATELY BEGIN PREPARATIONS FOR A POTENTIAL STRATEGIC TRANSACTION WHILE CO AWAITS U.S. FDA'S DECISION REGARDING BRINAVESS
* CORREVIO PHARMA - CO'S NDA SEEKING APPROVAL FOR BRINAVESS IS UNDER REVIEW BY FDA WITH TARGET ACTION DATE OF DEC 24, 2019 UNDER PDUFA
* CORREVIO PHARMA CORP - INTENDS TO REDUCE ITS OPERATING COSTS IN NORTH AMERICA
* CORREVIO PHARMA - CONCENTRATING ITS RESOURCES ON ONLY ESSENTIAL COMMERCIAL & BUSINESS DEVELOPMENT ACTIVITIES
* CORREVIO PHARMA CORP - HAS RETAINED PIPER JAFFRAY TO ASSIST IN ITS REVIEW OF STRATEGIC ALTERNATIVES